Atlantic Equities Maintains Neutral on AbbVie, Lowers Price Target to $162
Atlantic Equities analyst Steve Chesney maintains AbbVie (NYSE:ABBV) with a Neutral and lowers the price target from $178 to $162.
Recap Of Friday’s Biotech Catalysts – End of The Day Summary
The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE…
What Are Whales Doing With AbbVie
A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie.
Looking at options history for AbbVie (NYSE:ABBV) we detected 18 strange trades.
AbbVie’s Q2 Sales Marginally Shy Of Wall Street Estimates, Confirms Annual Profit Outlook
AbbVie Inc (NYSE:ABBV) reports Q2 adjusted EPS of $3.37, up 11.2% Y/Y and beating the consensus of $3.33. Overall sales…
Preview: AbbVie’s Earnings
AbbVie (NYSE:ABBV) is set to give its latest quarterly earnings report on Friday, 2022-07-29. Here's what investors need to know before the announcement.
Analysts estimate that AbbVie will report an earnings per share (EPS) of $3.33.
Daily Biotech Pulse: GSK’s Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion’s Schizophrenia Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours:
Allergan To End Around 3,000 Opioid Lawsuits With Over $2B In Settlement: Report
AbbVie Inc’s (NYSE:ABBV) Allergan unit has agreed to pay more than $2 billion to resolve over 3,000 lawsuits filed…
Recap of Wednesday’s Biotech Catalysts – End of The Day Summary
IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate…
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today
AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 6.43% on an annualized basis producing an average annual return of 16.28%. Currently, AbbVie has a market capitalization of $264.31 billion.
Recap Of Tuesday’s Biotech Catalysts – End of The Day Summary
European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg…